Clinical Trials Browser

CIMAvax EGF × Thoracic × 90 days × Clear all

NCT07543172 2026-04-21

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Neoplasms

NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Phase EARLY_PHASE1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive